Penn State Hershey Cancer Institute, Experimental Therapeutics A - CH74, Room T3319, 500 University Drive, Hershey, PA 17033-0850, USA.
Best Pract Res Clin Haematol. 2012 Jun;25(2):143-52. doi: 10.1016/j.beha.2012.03.001. Epub 2012 May 4.
Mantle cell lymphoma (MCL) is a rare, aggressive subtype of B cell NHL for which there is no standard of care. It is characterized by the t(11;14) translocation, implicating cyclin D1 (CCND1) in its pathogenesis. Cyclin D1 is one of a family of 3 unlinked D type cyclin genes, CCND1, 2, 3. CCND1 is not expressed in normal B cells. Deregulated expression occurs as a result of juxtaposition of cis IgH enhancer elements, Eμ and 3' Cα, to the cyclin D1 gene. These enhancer elements and regions upstream of the CCND1 gene are hypomethylated on the translocated allele. Histones surrounding the translocation have shown hyperacetylation as well, a hallmark of transcriptionally active chromatin. The t(11;14) translocation is an epigenetic event, leading to cyclin D1 deregulated transcription. These findings provide the rationale for the use of epigenetic and targeted cyclin D1 therapies to overcome resistance and induce durable remissions in MCL.
套细胞淋巴瘤(MCL)是一种罕见且侵袭性的 B 细胞 NHL,目前尚无标准治疗方法。其特征是存在 t(11;14)易位,这涉及到细胞周期蛋白 D1(CCND1)在发病机制中的作用。CCND1 是 3 个不相关的 D 型细胞周期蛋白基因家族之一,包括 CCND1、2、3。正常 B 细胞不表达 CCND1。由于顺式 IgH 增强子元件 Eμ 和 3' Cα 与细胞周期蛋白 D1 基因并列,导致其表达失调。易位等位基因上的这些增强子元件和 CCND1 基因上游区域呈低甲基化状态。围绕易位的组蛋白也表现出乙酰化过度,这是转录活性染色质的标志。t(11;14)易位是一种表观遗传事件,导致细胞周期蛋白 D1 转录失调。这些发现为使用表观遗传和靶向细胞周期蛋白 D1 治疗方法提供了依据,以克服耐药性并诱导 MCL 持久缓解。